Chloroquine and cardiovascular side effects

There has been increased interest in the use of chloroquine and hydroxychloroquine in the context of COVID-19 which is currently under evaluation in trials. There are potential cardiovascular side effects associated with its use.

We have summarised output from ESC meetings and journals related to this below.

Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review
Hypertrophic cardiomyopathy in a lupus patient: a case of hydroxychloroquine cardiotoxicity
Hot hearts on bone scintigraphy are not all amyloidosis: hydroxychloroquine-induced restrictive cardiomyopathy
Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus
Drug-induced arrhythmia: pharmacogenomic prescribing?
P362 Antimalarial-induced cardiomyopathy: retrospective case series
Hydroxychloroquine-induced restrictive cardiomyopathy: Correlation between clinical, Echocardiographic and pathologic finding
Chloroquine cardiotoxicity: a case of reversible cardiomyopathy
Chloroquine‐induced cardiomyopathy: a reversible cause of heart failure
Antimalarial-induced cardiomyopathy: retrospective case series
Chloroquine induced cardiomyopathy
Chloroquin cardiomyopathy manifested as hypertrophic cardiomyopathy